ArticleEMBO molecular medicine2024
ImmunoPET imaging of Trop2 in patients with solid tumours.
Article in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer.The Journal of clinical investigation · 2024Trial
- Preliminary Application of TROP2-Targeted Peptide Screening for Real-Time Intraoperative Navigation in Pancreatic Cancer.Chemical & biomedical imaging · 2026Article
- [Chemical & biomedical imaging · 2026Article
- Exploring a direct-lock NIR light-controlled strategy under APE1 gating: toward high-fidelity aptasensing in living biosamples via a sensitive auto-reinforcing iterative cascaded DNA nanobooster.Analytical and bioanalytical chemistry · 2026Article
- Non-competing Trop2 nanobody-based radiotheranostics for precision imaging and therapy of pancreatic cancer.Materials today. Bio · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting.EJNMMI research · 2026Review
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- Evaluation of albumin-binding PD-L1-targeted VHH for PET imaging in colorectal cancer.American journal of nuclear medicine and molecular imaging · 2026Article
- Trop2 immuno-PET/CT imaging of prostate cancer: a proof-of-concept translational study.BMC medicine · 2025Article
- Noninvasive Evaluation of Trop2 Expression UsingMolecular pharmaceutics · 2025Article
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
- Trends in nanobody radiotheranostics.European journal of nuclear medicine and molecular imaging · 2025Review
- Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.Nature reviews. Urology · 2025Review
- ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [Molecular pharmaceutics · 2025Article
- [American journal of nuclear medicine and molecular imaging · 2025Article
- TROP2-targeted molecular imaging: a promising tool for precision oncology.American journal of nuclear medicine and molecular imaging · 2025Review
- New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.Research (Washington, D.C.) · 2025Review
- Trop2-targeted immunoPET ligands.American journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Accurately predicting and selecting patients who can benefit from targeted or immunotherapy is crucial for precision therapy. Trophoblast cell surface antigen 2 (Trop2) has been extensively investigated as a pan-cancer biomarker expressed in various tumours and plays a crucial role in tumorigenesis through multiple signalling pathways. Our laboratory successfully developed two
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.